These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25102830)

  • 1. Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials.
    Cassese S; Byrne RA; Laugwitz KL; Schunkert H; Berger PB; Kastrati A
    EuroIntervention; 2015 Jun; 11(2):196-203. PubMed ID: 25102830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis.
    Mushahid H; Shah SA; Farhan SH; Shuja MH; Balasingam K; Siddiqui AA; Hameed I; Akram K; Mushahid S; Usman MS
    Am J Cardiovasc Drugs; 2024 May; 24(3):385-398. PubMed ID: 38683263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials.
    Bikdeli B; Erlinge D; Valgimigli M; Kastrati A; Han Y; Steg PG; Stables RH; Mehran R; James SK; Frigoli E; Goldstein P; Li Y; Shahzad A; Schüpke S; Mehdipoor G; Chen S; Redfors B; Crowley A; Zhou Z; Stone GW
    Circulation; 2023 Oct; 148(16):1207-1219. PubMed ID: 37746717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalirudin versus unfractionated heparin in patients with myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized controlled trials.
    Al-Abdouh A; Mhanna M; Jabri A; Madanat L; Alhuneafat L; Mostafa MR; Kundu A; Gupta V
    Cardiovasc Revasc Med; 2024 Apr; 61():52-61. PubMed ID: 37872022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bivalirudin versus heparin in contemporary percutaneous coronary interventions for patients with acute coronary syndrome: a systematic review and meta-analysis.
    Zhang J; Chen Z; Wang D; Li C; Luo F; He Y
    Cardiol J; 2024; 31(2):309-320. PubMed ID: 37964648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of bivalirudin versus heparin(s) during percutaneous coronary interventions in patients receiving prasugrel: a propensity-matched study.
    Hamon M; Bonello L; Marso S; Rao SV; Valgimigli M; Verheugt F; Gershlick A; Wang Y; Prats J; Steg GP; Deliargyris E
    Clin Cardiol; 2014 Jan; 37(1):14-20. PubMed ID: 24114942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis.
    Oli PR; Shrestha DB; Shtembari J; Gyawali P; Regmi L; Bhandari A; Dhungel S; Mattumpuram J; Pant K; Mungee S
    Coron Artery Dis; 2023 Dec; 34(8):562-579. PubMed ID: 37865864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial.
    Schüpke S; Hein-Rothweiler R; Mayer K; Janisch M; Sibbing D; Ndrepepa G; Hilz R; Laugwitz KL; Bernlochner I; Gschwendtner S; Kupka D; Gori T; Zeiher AM; Schunkert H; Massberg S; Kastrati A;
    Thromb Haemost; 2019 Sep; 119(9):1539-1545. PubMed ID: 31226721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Outcomes in Patients Requiring Mechanical Circulatory Support Who Received Cangrelor in Addition to Anticoagulation Versus Anticoagulation Alone.
    Martin TC; Duewell BE; Juul JJ; Rinka JRG; Rein L; Feih JT
    J Cardiothorac Vasc Anesth; 2024 Jun; 38(6):1328-1336. PubMed ID: 38521630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction-Outcomes at two years.
    Omerovic E; James S; Råmundal T; Fröbert O; Linder R; Danielewicz M; Hamid M; Pagonis C; Henareh L; Wagner H; Stewart J; Jensen J; Lindros P; Robertsson L; Wikström H; Ulvenstam A; Bhiladval P; Tödt T; Ioanes D; Kellerth T; Zagozdzon L; Götberg M; Andersson J; Angerås O; Östlund O; Held C; Koul S; Erlinge D
    Cardiovasc Revasc Med; 2024 Mar; ():. PubMed ID: 38575449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation Stability With Bivalirudin: Positioning the Horse Before the Cart.
    Chen JK; Salerno DM; Law S; Freniere V; Neunert C
    ASAIO J; 2023 Nov; 69(11):e468-e469. PubMed ID: 37220194
    [No Abstract]   [Full Text] [Related]  

  • 12. Bivalirudin Superiority in Pediatric Berlin Hearts: Too Early to Draw Conclusions?
    Seelhammer TG; Wieruszewski PM; Laudanski K
    ASAIO J; 2023 Nov; 69(11):e467. PubMed ID: 37220195
    [No Abstract]   [Full Text] [Related]  

  • 13. Bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome.
    Galli M; Gargiulo G; Benenati S; Mehran R; Angiolillo DJ
    Eur Heart J Cardiovasc Pharmacother; 2023 Nov; 9(7):666-668. PubMed ID: 37081774
    [No Abstract]   [Full Text] [Related]  

  • 14. Bivalirudin: The misunderstood alternative to heparin.
    Faraoni D; DiNardo JA
    Paediatr Anaesth; 2024 May; 34(5):394-395. PubMed ID: 38440919
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply: Pretreatment with unfractionated heparin in patients undergoing primary PCI: a standard of treatment together with DAPT?
    Emilsson OL; Koul S
    EuroIntervention; 2023 Apr; 18(17):1473-1474. PubMed ID: 37092267
    [No Abstract]   [Full Text] [Related]  

  • 16. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.
    Cavender MA; Sabatine MS
    Lancet; 2014 Aug; 384(9943):599-606. PubMed ID: 25131979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
    Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
    J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome.
    Navarese EP; Schulze V; Andreotti F; Kowalewski M; Kołodziejczak M; Kandzari DE; Rassaf T; Gorny B; Brockmeyer M; Meyer C; Berti S; Kubica J; Kelm M; Valgimigli M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):201-213. PubMed ID: 25616926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials.
    Lipinski MJ; Lhermusier T; Escarcega RO; Baker NC; Magalhães MA; Torguson R; Suddath WO; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2014; 15(6-7):315-22. PubMed ID: 25440505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.
    Valgimigli M; Frigoli E; Leonardi S; Rothenbühler M; Gagnor A; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andò G; Repetto A; Limbruno U; Garbo R; Sganzerla P; Russo F; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Presbitero P; Santarelli A; Sardella G; Varbella F; Tresoldi S; de Cesare N; Rigattieri S; Zingarelli A; Tosi P; van 't Hof A; Boccuzzi G; Omerovic E; Sabaté M; Heg D; Jüni P; Vranckx P;
    N Engl J Med; 2015 Sep; 373(11):997-1009. PubMed ID: 26324049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.